TARRYTOWN, N.Y., Nov. 21 /PRNewswire/ -- Bayer HealthCare, Diagnostics Division, a member of the Bayer Group , announced today the approval for sale of the new ADVIA Centaur(R) CP Immunoassay System. The ADVIA Centaur CP, part of the ADVIA family of automated clinical laboratory solutions from Bayer Diagnostics, is a compact, benchtop, fully automated analytical system which enables hospital and reference laboratories to rapidly perform a wide variety of disease-specific tests which enhance the management of disease.
(Photo: http://www.newscom.com/cgi-bin/prnh/20051121/NYM143 )
Following in the footsteps of the market-leading ADVIA Centaur Immunoassay system, the ADVIA Centaur CP includes many unique productivity enhancement features. Additionally, it uses the same proven assay methodologies and reagent packs as the ADVIA Centaur. The complete menu of disease state assay groups available on both the ADVIA Centaur and ADVIA Centaur CP includes cardiovascular, oncology, fertility, and infectious disease testing capabilities.
The ADVIA Centaur CP, with its chemistry counterpart, the ADVIA(R) 1200 Clinical Chemistry System, working with Bayer’s networking and data management solution, ADVIA CentraLink(R), delivers synergies of sample handling, connectivity and system functionality to provide a complete immunoassay and clinical chemistry solution. This enables the smaller lab to offer a complete testing service without costly sample splitting and result collation.
“The ADVIA Centaur CP is a key component of our strategy to better serve our customers by offering more analytical platforms, more assays and improved connectivity and integration,” said Tony Bihl, President, Bayer Diagnostics. “Our objective at Bayer Healthcare is to be the preferred partner and provider of solutions, both to the high-end, high-volume, fully automated laboratory, and now, with the introduction of the ADVIA Centaur CP, to the mid-sized laboratory in the community hospital, IDN satellite or private facility.”
“Our customers have clearly told us that they have a need for an immunoassay platform that packages ADVIA Centaur(R) Immunoassay System technology in a smaller footprint,” said Tom Warekois, SVP of Global Strategic Marketing, Bayer Diagnostics. “The ADVIA Centaur CP enables the mid-size and specialty laboratory to make improvements in productivity by consolidating testing onto a single platform sized for their laboratory needs.”
About Bayer HealthCare, Diagnostics Division
Bayer HealthCare, Diagnostics Division (www.bayerdiag.com), based in Tarrytown, New York, U.S.A., is one of the largest diagnostic businesses in the world. The organization supports customers in 100 countries through an extensive portfolio of laboratory testing, molecular testing and near patient care diagnostics systems and services for use in the assessment and management of health, including the areas of cardiovascular and kidney diseases, oncology, virology and women’s health. Bayer HealthCare Diagnostics Division’s global headquarters in the United States operates as part of Bayer HealthCare LLC, a member of the worldwide Bayer HealthCare group.
About Bayer HealthCare AG
Bayer HealthCare AG, a subsidiary of Bayer AG, is one of the world’s leading, innovative companies in the health care and medical products industry. In 2004, the Bayer HealthCare subgroup generated sales amounting to some 8.5 billion Euro. The company combines the global activities of the divisions Animal Health, Biological Products, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. Bayer HealthCare employed 35,300 people worldwide in 2004. Bayer HealthCare’s aim is to discover and manufacture innovative products that will improve human and animal health worldwide. The products enhance well-being and quality of life by diagnosing, preventing and treating disease.
This news release contains forward-looking statements based on current assumptions and forecasts made by Bayer Group management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in our public reports filed with the Frankfurt Stock Exchange and with the U.S. Securities and Exchange Commission (including our Form 20-F). The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20051121/NYM143AP Archive: http://photoarchive.ap.orgAP PhotoExpress Network: PRN7PRN Photo Desk, photodesk@prnewswire.comBayer HealthCare, Diagnostics Division
CONTACT: Marianne Flanagan, Bayer Diagnostics, +1-914-366-1825
Web site: http://www.bayerdiag.com/
